Table 1

Top GWAS loci (P < 1 × 10−5) associated with cardiovascular mortality: effects in the intensive and standard glycemic treatment arms

Intensive arm (n = 2,667)Standard arm (n = 2,693)Overall
Closest gene*SNPPositionMAF§HR (95% CI)PHR (95% CI)PP for interaction
MGMTrs929987010:1312693090.083.58 (2.32–5.55)9.77E-090.96 (0.48–1.92)0.910.0042
LINC01333rs579225:735779390.482.65 (1.88–3.72)2.04E-081.07 (0.75–1.53)0.720.0004
MASP2rs3739466181:110887740.084.00 (2.40–6.68)1.15E-070.86 (0.33–2.24)0.750.0026
AX748080rs7952544211:439909320.062.98 (1.96–4.54)3.63E-071.62 (0.84–3.13)0.150.0897
CCNJLrs68789705:1597717530.063.10 (2.00–4.81)4.68E-071.31 (0.66–2.59)0.440.0399
ANKFN1rs11689900317:544485670.052.86 (1.87–4.39)1.35E-061.34 (0.68–2.64)0.410.0777
GALNT18rs148712211:114726170.062.98 (1.90–4.69)2.19E-062.10 (1.15–3.85)0.020.3206
LINC01102rs2004575312:1046945100.212.27 (1.61–3.20)2.63E-061.03 (0.64–1.66)0.900.0064
KIF2Brs7976150517:515888710.062.67 (1.77–4.03)3.09E-061.56 (0.82–2.97)0.170.1779
PCGEM1rs2001846812:1942594690.053.29 (1.99–5.43)3.31E-061.09 (0.38–3.13)0.870.0575
RASAL2rs22091691:1786014920.422.09 (1.53–2.86)4.07E-061.36 (0.95–1.96)0.090.0949
TMEM189rs5575791920:487485480.212.13 (1.54–2.95)4.79E-060.91 (0.58–1.42)0.670.0017
ACTL7Brs1426311179:1116141170.072.63 (1.73–3.98)5.13E-061.09 (0.53–2.26)0.810.0508
IKZF2rs561758572:2139294650.102.58 (1.72–3.88)5.25E-061.02 (0.53–1.96)0.950.0171
MIR548I1rs1404327953:1255187390.053.29 (1.97–5.48)5.25E-060.75 (0.27–2.05)0.570.0117
MIR_584rs729477636:1150417830.062.99 (1.86–4.82)6.17E-061.20 (0.54–2.64)0.650.0456
SETBP1rs5616142818:425242780.062.76 (1.78–4.29)6.31E-060.83 (0.37–1.89)0.660.0163
LOC155060rs69748477:1489989600.252.09 (1.52–2.88)6.92E-061.10 (0.73–1.66)0.640.0124
SLC25A26rs789744413:663438050.092.63 (1.72–4.02)7.94E-061.32 (0.78–2.22)0.300.0432
CNPY1rs559075177:1553020200.072.77 (1.77–4.33)8.32E-060.25 (0.06–1.01)0.050.0040
PER4rs1118916167:94374620.082.67 (1.73–4.11)8.51E-061.45 (0.75–2.81)0.270.1971
ERMAPrs124066431:433115630.182.14 (1.53–2.99)9.12E-060.93 (0.57–1.50)0.760.0103
SUMO1P1rs6220665320:525380790.063.10 (1.88–5.12)9.33E-061.41 (0.68–2.94)0.360.1021
PFKPrs5875104110:30074940.162.19 (1.55–3.10)9.77E-060.77 (0.43–1.38)0.380.0018
  • Primary analysis includes adjustment for assignment to blood pressure and lipid subtrials, interventions within these subtrials, seven clinical center networks, and top three principal components. These are results of meta-analysis of the ANYSET and ACCSET; results within individual sets are shown in Supplementary Table 5. Other adjusted analyses are shown in Supplementary Table 6.

  • *Closest gene within 500 kbp of the SNP.

  • †One representative per locus.

  • ‡Position is chromosome:bp. Position according to the National Center for Biotechnology Information assembly build GRCh37/hg19.

  • §Here MAF is the average of the minor allele frequencies of ANYSET and ACCSET.

  • ¶Effect of SNP × treatment interaction.